American Well Corporation operates as a telehealth company that enables digital delivery of care for healthcare. Its application offers urgent care; pediatrics; therapy; menopause nutrition; menopause counseling; telestroke; population health management; telepsychiatry; pregnancy and postpartum care; pregnancy and postpartum therapy; breastfeed support; and menopause care. The company also provides telemedicine equipment, including telemedicine carts, peripherals, TV kits, tablets, and kiosks. American Well Corporation was incorporated in 2006 and is headquartered in Boston, Massachusetts.
IPO Year: 2020
Exchange: NYSE
Website: amwell.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/3/2023 | $5.00 → $2.50 | Overweight → Equal-Weight | Morgan Stanley |
| 3/23/2023 | $5.00 → $2.50 | Outperform → Market Perform | TD Cowen |
| 2/27/2023 | $5.00 → $3.50 | Overweight → Neutral | Piper Sandler |
| 1/4/2023 | $4.20 | Neutral → Buy | BofA Securities |
| 9/7/2022 | $5.00 | Hold | Truist |
| 4/14/2022 | $6.00 | Buy | Guggenheim |
| 4/1/2022 | $5.00 | Neutral | Credit Suisse |
| 2/28/2022 | $6.00 → $4.00 | Equal-Weight | Wells Fargo |
| 2/11/2022 | $6.00 | Neutral | Goldman |
| 12/17/2021 | $12.00 → $9.00 | Overweight | Morgan Stanley |
BOSTON, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leader in digital care, today announced that, on November 4, 2024, it made a grant of restricted stock units ("RSUs") covering 254,227 shares of its Class A common stock to Mark Hirschhorn. The grant was offered as material inducement to Mr. Hirschhorn's employment as Amwell's chief financial officer. The RSUs become vested as follows, subject to Mr. Hirschhorn's continued employment through each vesting date, except as noted below: 25% of the RSUs vested on the grant date, and the remaining 75% of the RSUs will vest in substantially equal quarterly installments over a three-year period, starting on the one-year anniversary o
BOSTON, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL) a small-cap, growth healthcare company and a leading provider of healthcare software as a service, today announced financial results for the third quarter ended Sept. 30, 2024. Visit Amwell's investor relations website at investors.amwell.com to view the third quarter 2024 earnings report. The company will host a conference call to discuss its financial results today at 5 p.m. ET, Oct. 30. The call can be accessed via a live audio webcast at investors.amwell.com or by dialing 1-888-510-2008 for U.S. participants or 1-646-960-0306 for international participants, referencing conference ID number 7830032. A replay of the call will
BOSTON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leader in digital care, announced company leaders will participate in several upcoming investor conferences. Ido Schoenberg, M.D., Amwell chairman and chief executive officer, and Mark Hirschhorn, Amwell chief financial officer, will participate in fireside chats or one-on-one meetings at these events: Nov. 12: UBS Global Healthcare Conference in Palos Verdes, Calif. The fireside chat is at 8:45 a.m. PT.Nov. 20: Needham 4th Annual Consumer Tech Conference. Virtual one-on-one meetings throughout the day.Nov. 25: The BTIG Virtual Health Forum. Virtual one-on-one meetings throughout the day.Dec. 4: The Piper Sandler 36th Annual
BOSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leader in digital care, today announced Mark Hirschhorn will become Amwell Chief Financial Officer (CFO) effective Oct. 21, succeeding Robert "Bob" Shepardson, who has been in the role since 2021. Hirschhorn will oversee Amwell's financial operations, enterprisewide optimization and capital allocation activities, and will play a meaningful leadership role in guiding the company's strategy to support its long-term growth objectives and enhance shareholder value. Hirschhorn is a healthcare technology industry leader, with over three decades of experience in financial and strategic operations, having served in senior executiv
BOSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leader in digital care, will report third quarter 2024 operating results on Wednesday, Oct. 30. Following the distribution of the earnings alert via wire services, the Amwell management team will host a live conference call and webcast at 5 p.m. ET to review the company's operating results and provide a general business update. The full earnings report and the live audio webcast can be accessed by visiting the Investors section of the company's website. A webcast replay of the call will be available at investors.amwell.com for approximately 90 days. About Amwell Amwell is a leading hybrid care, delivery enablement platfor
Boston, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leader in hybrid care enablement, announced that the company will participate in several investor conferences in September. Ido Schoenberg, M.D., Amwell's chairman and CEO, and Robert Shepardson, Amwell's CFO, will participate in the following conferences via fireside chat and one-on-one meetings held throughout the day: September 4, Morgan Stanley 22nd Annual Global Healthcare Conference in New York City; fireside chat at 1:50 p.m. ET. September 5, Wells Fargo Healthcare Conference in Boston (one-on-one meetings only). On September 10, Mr. Shepardson will participate in one-on-one investor meetings at the Baird Healt
Boston, July 31, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL) a small-cap, growth healthcare company and a leading provider of healthcare software as a service, today announced financial results for the second quarter ended June 30, 2024. Visit Amwell's investor relations website at investors.amwell.com to view the second quarter 2024 earnings report. The company will host a conference call to discuss its financial results today at 5 p.m. ET, Wednesday, July 31. The call can be accessed via a live audio webcast at investors.amwell.com or by dialing 1-888-510-2008 for U.S. participants or 1-646-960-0306 for international participants, referencing conference ID number 7830032. A replay o
Boston, July 17, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leader in hybrid care enablement, will report its second quarter 2024 operating results on Wednesday, July 31. Following the distribution of the earnings release via wire services, the Amwell management team will host a live conference call and webcast at 5 p.m. ET to review the company's operating results and provide a general business update. The audio webcast can be accessed by visiting the Investors section of the company's website. Alternatively, participants can call (888) 510-2008 (U.S.) or (646) 960-0306 (International) to listen to the live conference call. The call ID number is 7830032. A webcast replay of th
Boston, June 28, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a small-cap growth healthcare company and a leading provider of healthcare software as a service, today announced that its Board of Directors (the "Board") has approved a 1-for-20 reverse stock split ("Reverse Split") of its Class A common stock, Class B common stock and Class C common stock (collectively, the "Common Stock"), that is expected to become effective on July 10, 2024 at 5:00 p.m. EDT. The shares of the Company's Class A common stock are expected to begin trading on the New York Stock Exchange ("NYSE") on a split-adjusted basis at the market open on July 11, 2024. No change will be made to the trading symbol for the
Boston, June 17, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leader in hybrid care enablement, today announces the appointment of Ricky Goldwasser to the company's Board of Directors, effective June 13. "Ricky brings to our board a deep financial background that makes her an invaluable addition as we focus on Amwell's path to profitability. Ricky's strong voice coupled with her impressive track record will help guide Amwell as we strive for greater efficiencies, optimized cash flow and profitable growth, while remaining committed to enabling our clients to achieve their goals. We are pleased to welcome Ricky to the team," said Ido Schoenberg, M.D., CEO and chairman, Amwell. Ms. Gol
144 - American Well Corp (0001393584) (Subject)
S-8 - American Well Corp (0001393584) (Filer)
8-K - American Well Corp (0001393584) (Filer)
10-Q - American Well Corp (0001393584) (Filer)
8-K - American Well Corp (0001393584) (Filer)
8-K - American Well Corp (0001393584) (Filer)
8-K - American Well Corp (0001393584) (Filer)
10-Q - American Well Corp (0001393584) (Filer)
8-K - American Well Corp (0001393584) (Filer)
8-K - American Well Corp (0001393584) (Filer)
BOSTON, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL) a small-cap, growth healthcare company and a leading provider of healthcare software as a service, today announced financial results for the third quarter ended Sept. 30, 2024. Visit Amwell's investor relations website at investors.amwell.com to view the third quarter 2024 earnings report. The company will host a conference call to discuss its financial results today at 5 p.m. ET, Oct. 30. The call can be accessed via a live audio webcast at investors.amwell.com or by dialing 1-888-510-2008 for U.S. participants or 1-646-960-0306 for international participants, referencing conference ID number 7830032. A replay of the call will
BOSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leader in digital care, will report third quarter 2024 operating results on Wednesday, Oct. 30. Following the distribution of the earnings alert via wire services, the Amwell management team will host a live conference call and webcast at 5 p.m. ET to review the company's operating results and provide a general business update. The full earnings report and the live audio webcast can be accessed by visiting the Investors section of the company's website. A webcast replay of the call will be available at investors.amwell.com for approximately 90 days. About Amwell Amwell is a leading hybrid care, delivery enablement platfor
Boston, July 31, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL) a small-cap, growth healthcare company and a leading provider of healthcare software as a service, today announced financial results for the second quarter ended June 30, 2024. Visit Amwell's investor relations website at investors.amwell.com to view the second quarter 2024 earnings report. The company will host a conference call to discuss its financial results today at 5 p.m. ET, Wednesday, July 31. The call can be accessed via a live audio webcast at investors.amwell.com or by dialing 1-888-510-2008 for U.S. participants or 1-646-960-0306 for international participants, referencing conference ID number 7830032. A replay o
Boston, July 17, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leader in hybrid care enablement, will report its second quarter 2024 operating results on Wednesday, July 31. Following the distribution of the earnings release via wire services, the Amwell management team will host a live conference call and webcast at 5 p.m. ET to review the company's operating results and provide a general business update. The audio webcast can be accessed by visiting the Investors section of the company's website. Alternatively, participants can call (888) 510-2008 (U.S.) or (646) 960-0306 (International) to listen to the live conference call. The call ID number is 7830032. A webcast replay of th
Boston, May 01, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL) a small-cap, growth healthcare company and a leading provider of healthcare software as a service, today announced financial results for the first quarter ended March 31, 2024. Visit Amwell's investor relations website at investors.amwell.com to view the first quarter 2024 earnings report. The company will host a conference call to discuss its financial results today at 5 p.m. ET, Wednesday, May 1. The call can be accessed via a live audio webcast at investors.amwell.com or by dialing 1-888-510-2008 for U.S. participants or 1-646-960-0306 for international participants, referencing conference ID #7830032. A replay of the call
Boston, April 17, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leader in hybrid care enablement, will report its first quarter 2024 operating results Wednesday, May 1. Following the distribution of the earnings release via wire services, the Amwell management team will host a live conference call and webcast at 5 p.m. ET to review the company's operating results and provide a general business update. The audio webcast can be accessed by visiting the Investors section of the company's website. Alternatively, participants can call (888) 510-2008 (U.S.) or (646) 960-0306 (International) to listen to the live conference call. The call ID number is 7830032. A webcast replay of the cal
Boston, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL) a leader in hybrid care enablement, today announced financial results for the fourth quarter and full year ended Dec. 31, 2023. Amwell is a small-cap growth company and a leading provider of healthcare software as a service. Visit Amwell's investor relations website at investors.amwell.com to view the fourth quarter and full year 2023 earnings report. Amwell will host a conference call to discuss its financial results today at 5 p.m. ET, Wednesday, Feb.14. The call can be accessed via a live audio webcast at investors.amwell.com or by dialing 1-888-510-2008 for U.S. participants, or 1-646-960-0306 for international partic
Boston, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leader in digital healthcare enablement, will report its fourth quarter 2023 operating results on Wednesday, Feb. 14. Following the distribution of the earnings release via wire services, the Amwell management team will host a live conference call and webcast at 5 p.m. ET to review the company's operating results and provide a general business update. The audio webcast can be accessed by visiting the Investors section of the company's website. Alternatively, participants can call (888) 510-2008 (U.S.) or (646) 960-0306 (International) to listen to the live conference call. The call ID number is 7830032. A webcast re
Amwell® (NYSE:AMWL), a leader in hybrid care enablement, today announced financial results for the third quarter ended Sept. 30, 2023. Amwell Third Quarter 2023 Highlights: Recorded Total Revenue of $61.9 million Achieved subscription revenue of $28.4 million Recorded Amwell Medical Group ("AMG") visit revenue of $26.7 million Reported gross margin of 35% Net loss was ($137.1) million, compared to ($93.5) million in second quarter of 2023. Net loss reflects non-cash goodwill impairment charges of $78.9 million recorded in the third quarter of 2023 and $27.3 million recorded in the second quarter of 2023 Adjusted EBITDA improved to ($38.5) million compared to ($45.3) mi
Amwell® (NYSE:AMWL), a leader in hybrid health care enablement, today announced it will report its third-quarter 2023 operating results on Wednesday, November 1, 2023. Following distribution of the earnings release via wire services, the Amwell management team will host a live conference call and webcast at 5 p.m. Eastern time to review the company's operating results and provide a general business update. A live audio webcast can be accessed by visiting the Investors section of the company's website at investors.amwell.com. Alternatively, please call (888) 510-2008 (U.S.) or (646) 960-0306 (International) to listen to the live conference call. The conference ID number for the live call w
4 - American Well Corp (0001393584) (Issuer)
4 - American Well Corp (0001393584) (Issuer)
4 - American Well Corp (0001393584) (Issuer)
4 - American Well Corp (0001393584) (Issuer)
3 - American Well Corp (0001393584) (Issuer)
4 - American Well Corp (0001393584) (Issuer)
4 - American Well Corp (0001393584) (Issuer)
4 - American Well Corp (0001393584) (Issuer)
4 - American Well Corp (0001393584) (Issuer)
4 - American Well Corp (0001393584) (Issuer)
SC 13G/A - American Well Corp (0001393584) (Subject)
SC 13G - American Well Corp (0001393584) (Subject)
SC 13G - American Well Corp (0001393584) (Subject)
SC 13G/A - American Well Corp (0001393584) (Subject)
SC 13G/A - American Well Corp (0001393584) (Subject)
SC 13G/A - American Well Corp (0001393584) (Subject)
SC 13G/A - American Well Corp (0001393584) (Subject)
SC 13G/A - American Well Corp (0001393584) (Subject)
SC 13G/A - American Well Corp (0001393584) (Subject)
SC 13G/A - American Well Corp (0001393584) (Subject)
UBS analyst Kevin Caliendo maintains American Well (NYSE:AMWL) with a Neutral and lowers the price target from $1.5 to $0.6.
Needham analyst Ryan MacDonald reiterates American Well (NYSE:AMWL) with a Hold.
American Well (NYSE:AMWL) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.19) by 31.58 percent. The company reported quarterly sales of $59.522 million which missed the analyst consensus estimate of $60.524 million by 1.66 percent. This is a 7.00 percent decrease over sales of $64.001 million the same period last year.
Morgan Stanley analyst Craig Hettenbach maintains American Well (NYSE:AMWL) with a Equal-Weight and lowers the price target from $1.75 to $1.
Shares of Herbalife Ltd. (NYSE:HLF) fell sharply in today’s session following weak quarterly earnings. Herbalife posted adjusted earnings of 28 cents per share, missing market estimates of 39 cents per share. The company’s quarterly sales came in at $1.22 billion versus expectations of $1.19 billion. Herbalife shares dipped 35.7% to $7.55 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers JX Luxventure Limited (NASDAQ:JXJT) shares jumped 377% to $6.21 following H1 results. Dunxin Financial Holdings Limited (NYSE:DXF) surged 204% to $1.11 after gaining around 5% on Wednesday. China Natural Resources, Inc. (NASDAQ:CHNR) jumped 143% to $2.68 after gain
BOSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leader in digital care, today announced Mark Hirschhorn will become Amwell Chief Financial Officer (CFO) effective Oct. 21, succeeding Robert "Bob" Shepardson, who has been in the role since 2021. Hirschhorn will oversee Amwell's financial operations, enterprisewide optimization and capital allocation activities, and will play a meaningful leadership role in guiding the company's strategy to support its long-term growth objectives and enhance shareholder value. Hirschhorn is a healthcare technology industry leader, with over three decades of experience in financial and strategic operations, having served in senior executiv
Boston, June 17, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leader in hybrid care enablement, today announces the appointment of Ricky Goldwasser to the company's Board of Directors, effective June 13. "Ricky brings to our board a deep financial background that makes her an invaluable addition as we focus on Amwell's path to profitability. Ricky's strong voice coupled with her impressive track record will help guide Amwell as we strive for greater efficiencies, optimized cash flow and profitable growth, while remaining committed to enabling our clients to achieve their goals. We are pleased to welcome Ricky to the team," said Ido Schoenberg, M.D., CEO and chairman, Amwell. Ms. Gol
ALACHUA, Fla. and TAMPA, Fla., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, is pleased to announce today the appointment of Mrs. Kathy Weiler to its Board of Directors, effective December 20, 2023. Weiler, a senior executive with 20+ years of experience and proven track record in driving strategic commercial initiatives, will serve on the Board's Governance, Nominating and Sustainability Committee, and the Quality, Compliance, and Portfolio Management Committee. "I am happy to welcome Kathy to the Board as Axogen is approaching an exciting inflection point in its journ
The Amwell Converge™ platform will enable DHA healthcare teams to deliver connected and seamless in-person, virtual, and automated care delivery for the Military Health System Amwell® (NYSE:AMWL), a leader in hybrid healthcare enablement, together with Leidos (NYSE:LDOS), a FORTUNE® 500 science and technology leader, was recently awarded a next-generation contract to provide a hybrid care technology platform designed to power the "Digital First" transformation of the Military Health System (MHS). Under this task order, the Leidos Partnership for Defense Health (LPDH) will deliver Amwell Converge™, a comprehensive hybrid care enablement platform designed to power the full continuum of ca
Industry veteran brings decades of experience driving growth initiatives for top healthcare companies to fuel growth at Amwell Amwell® (NYSE:AMWL), a leader in digital healthcare enablement, today announced the appointment of Kathy Weiler as Executive Vice President, Chief Commercial and Growth Officer, effective June 1, 2023. As a member of Amwell's executive leadership team, Weiler will lead the company's growth strategy, driving strategic initiatives and leading the business development, sales and account management, commercial enablement, marketing, and strategic and channel partnerships teams. Weiler will partner with Amwell clients to help them achieve greater clinical, operational
Amwell®, (NYSE:AMWL) a leader in digital healthcare enablement, today announced the appointment of Robert Webb to the Company's Board of Directors, effective immediately. Mr. Webb will further strengthen the Amwell Board and market position, bringing deep healthcare technology leadership experience, stemming from his more than 30 years as a growth executive, operator, and investor. "As healthcare organizations prioritize digital care to improve patient, member and provider experiences, address workforce shortages, streamline workflows and improve clinical and financial outcomes, Amwell's role as a digital transformation partner has never been more apparent," said Dr. Ido Schoenberg, Chairm
Innovative physician leader brings more than two decades experience to Amwell clinical, go to market and customer success initiatives Amwell® (NYSE:AMWL), a digital care delivery leader, has named Dr. Carrie Nelson as its new Chief Medical Officer. In this role, Dr. Nelson will focus on empowering provider and payer organizations as they seek to achieve greater clinical, operational, and financial outcomes through digital care delivery powered by Converge™, Amwell's enterprise-grade infrastructure software platform. Dr. Nelson will also be responsible for leading clients in their improvement of population health in today's new era of hybrid healthcare and will have clinical oversight of he
Mr. Shepardson will join Amwell on October 31st and will succeed current CFO Keith Anderson following a transition period Amwell®, (NYSE:AMWL) a national telehealth leader, today announced the appointment of Robert Shepardson to the position of Chief Financial Officer (CFO) and Head of Mergers & Acquisitions (M&A). Mr. Shepardson will join the company as CFO on October 31st and will work together during a transition period through the end of 2021 with current CFO Keith W. Anderson. With over 30 years of investment banking and capital markets experience across multiple high-growth sectors, Shepardson brings unmatched expertise in structuring strategic partnerships, restructurings, and debt
Healthcare Industry Veteran O'Grady to Head Growth Organization Amwell®, (NYSE:AMWL) a national telehealth leader, today announced the appointment of Brendan O'Grady to the position of Chief Commercial & Growth Officer, effective immediately. Mr. O'Grady will report to Amwell's Chairman and Co-CEO Ido Schoenberg. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210722005157/en/Brendan O'Grady (Photo: Business Wire) "Brendan has been a meaningful contributor to Amwell's strategy and growth since joining our Board in 2015," said Ido Schoenberg, Chairman and Co-CEO. "His long and impressive track record successfully leading large sca
Morgan Stanley downgraded Amwell from Overweight to Equal-Weight and set a new price target of $2.50 from $5.00 previously
TD Cowen downgraded Amwell from Outperform to Market Perform and set a new price target of $2.50 from $5.00 previously
Piper Sandler downgraded Amwell from Overweight to Neutral and set a new price target of $3.50 from $5.00 previously
BofA Securities upgraded Amwell from Neutral to Buy and set a new price target of $4.20
Truist initiated coverage of Amwell with a rating of Hold and set a new price target of $5.00
Guggenheim initiated coverage of Amwell with a rating of Buy and set a new price target of $6.00
Credit Suisse resumed coverage of Amwell with a rating of Neutral and set a new price target of $5.00
Wells Fargo reiterated coverage of American Well with a rating of Equal-Weight and set a new price target of $4.00 from $6.00 previously
Goldman initiated coverage of Amwell with a rating of Neutral and set a new price target of $6.00
Morgan Stanley reiterated coverage of American Well with a rating of Overweight and set a new price target of $9.00 from $12.00 previously